Liver Transplant Unit, Liver Unit, IDIBAPS, CIBERehd, Hospital Clínic, Barcelona, Spain.
Liver Unit, Hospital Italiano, Buenos Aires, Argentina.
Hepatology. 2018 May;67(5):1683-1694. doi: 10.1002/hep.29557. Epub 2018 Mar 24.
Sustained virological response (SVR) improves survival in post-liver transplant (LT) recurrent hepatitis C. However, the impact of SVR on fibrosis regression is not well defined. In addition, the performance of noninvasive methods to evaluate the presence of fibrosis and portal hypertension (PH) post-SVR has been scarcely evaluated. We aimed to investigate the degree of fibrosis regression (decrease ≥1 METAVIR stage) after-SVR and its associated factors in recurrent hepatitis C, as well as the diagnostic capacity of noninvasive methods in the assessment of liver fibrosis and PH after viral clearance. We evaluated 112 hepatitis C virus-infected LT recipients who achieved SVR between 2001 and 2015. A liver biopsy was performed before treatment and 12 months post-SVR. Hepatic venous pressure gradient (HVPG), liver stiffness measurement (LSM), and Enhanced Liver Fibrosis (ELF) score were also determined at the same time points. Sixty-seven percent of the cohort presented fibrosis regression: 43% in recipients with cirrhosis and 72%-85% in the remaining stages (P = 0.002). HVPG, LSM, and ELF significantly decreased post-SVR. Liver function significantly improved, and survival was significantly better in patients achieving fibrosis regression. Baseline HVPG and LSM as well as decompensations before therapy were independent predictors of fibrosis regression. One year post-SVR, LSM had a high diagnostic accuracy to discard the presence of advanced fibrosis (AF) and clinically significant PH (AUROC, 0.902 and 0.888).
In conclusion, SVR post-LT induces fibrosis regression in most patients, leading to significant clinical benefits. Pretreatment HVPG and LSM are significant determinants of the likelihood of fibrosis regression. Finally, LSM accurately predicts the presence of AF and PH 1 year after SVR and thus can be used to determine monitoring strategies. (Hepatology 2018;67:1683-1694).
本研究旨在探讨肝移植(LT)后复发丙型肝炎患者获得持续病毒学应答(SVR)后纤维化消退的程度及其相关因素,以及非侵入性方法在评估病毒清除后纤维化和门静脉高压(PH)中的诊断能力。
我们评估了 112 名在 2001 年至 2015 年间获得 SVR 的丙型肝炎病毒感染 LT 受者。在治疗前和 SVR 后 12 个月进行了肝活检。同时还测定了肝静脉压力梯度(HVPG)、肝硬度测量(LSM)和增强肝脏纤维化(ELF)评分。
67%的队列出现纤维化消退:肝硬化患者中 43%,其余阶段中 72%-85%(P = 0.002)。SVR 后 HVPG、LSM 和 ELF 显著降低。获得纤维化消退的患者肝功能明显改善,生存率明显提高。基线 HVPG 和 LSM 以及治疗前的失代偿是纤维化消退的独立预测因子。SVR 后 1 年,LSM 对排除晚期纤维化(AF)和临床显著 PH 具有较高的诊断准确性(AUROC 分别为 0.902 和 0.888)。
LT 后 SVR 可诱导大多数患者的纤维化消退,带来显著的临床获益。治疗前 HVPG 和 LSM 是纤维化消退可能性的重要决定因素。最后,LSM 可准确预测 SVR 后 1 年 AF 和 PH 的存在,因此可用于确定监测策略。(Hepatology 2018;67:1683-1694)